| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;99:1540-1547.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease and Serological Evidence for Chlamydia pneumoniae Infection
The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study
From the Department of Medicine, Division of Cardiology, University of Utah, LDS Hospital, Salt Lake City, Utah.
Correspondence to J. Brent Muhlestein, MD, or Jeffrey L. Anderson, MD, Coprincipal Investigators, Division of Cardiology, LDS Hospital, 8th Ave & C St, Salt Lake City, UT 84143.
Background—Chlamydia pneumoniae commonly causes respiratory infection, is vasotropic, causes atherosclerosis in animal models, and has been found in human atheromas. Whether it plays a causal role in clinical coronary artery disease (CAD) and is amenable to antibiotic therapy is uncertain.
Methods and Results—CAD patients (n=302) who had a seropositive
reaction to C pneumoniae (IgG titers 
1:16) were
randomized to receive placebo or azithromycin, 500 mg/d for 3 days,
then 500 mg/wk for 3 months. Circulating markers of inflammation
(C-reactive protein [CRP], interleukin [IL]-1, IL-6, and tumor
necrosis factor [TNF]-
), C pneumoniae antibody
titers, and cardiovascular events were assessed at 3
and 6 months. Treatment groups were balanced, with age averaging 64
(SD=10) years; 89% of the patients were male. Azithromycin reduced a
global rank sum score of the 4 inflammatory markers at 6 (but not 3)
months (P=0.011) as well as the mean global rank sum
change score: 531 (SD=201) for active drug and 587 (SD=190) for placebo
(P=0.027). Specifically, change-score ranks were
significantly lower for CRP (P=0.011) and IL-6
(P=0.043). Antibody titers were unchanged, and number of
clinical cardiovascular events at 6 months did not
differ by therapy (9 for active drug, 7 for placebo). Azithromycin
decreased infections requiring antibiotics (1 versus 12 at 3 months,
P=0.002) but caused more mild, primarily
gastrointestinal, adverse effects (36 versus 17,
P=0.003).
Conclusions—In CAD patients positive for C pneumoniae antibodies, global tests of 4 markers of inflammation improved at 6 months with azithromycin. However, unlike another smaller study, no differences in antibody titers and clinical events were observed. Longer-term and larger studies of antichlamydial therapy are indicated.
Key Words: Chlamydia pneumoniae • antibiotics • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berman, D. Hasdai, E. Raanani, G. P. Georghiou, L. Kapustin, Y. Chepurko, B. A. Vidne, and E. Hochhauser Ex-vivo effect of roxithromycin on human and rat arterial vasoactivity Interactive CardioVascular and Thoracic Surgery, June 1, 2005; 4(3): 232 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Berg, B. Maraha, A. van der Zee, S. K. Gielis, P. J. M. Roholl, G.-J. Scheffer, M. F. Peeters, and J. A. J. W. Kluytmans Effect of Clarithromycin Treatment on Chlamydia pneumoniae in Vascular Tissue of Patients with Coronary Artery Disease: a Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Microbiol., March 1, 2005; 43(3): 1325 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Sheehan, P M Kearney, S O Sullivan, C Mongan, E Kelly, and I J Perry Acute coronary syndrome and chronic infection in the Cork coronary care case-control study Heart, January 1, 2005; 91(1): 19 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tormakangas, H. Alakarppa, D. B. David, M. Leinonen, and P. Saikku Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3655 - 3661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Alpert New and Emerging Theories of Cardiovascular Disease: Infection and Elevated Iron Biol Res Nurs, July 1, 2004; 6(1): 3 - 10. [Abstract] [PDF]
|
|
|
|
|
|
P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Tousoulis, G Davies, C Stefanadis, P Toutouzas, and J A Ambrose Inflammatory and thrombotic mechanisms in coronary atherosclerosis Heart, September 1, 2003; 89(9): 993 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Berg, B. Maraha, G.-J. Scheffer, M. F. Peeters, and J. A. J. W. Kluytmans Effect of Clarithromycin on Inflammatory Markers in Patients with Atherosclerosis Clin. Vaccine Immunol., July 1, 2003; 10(4): 525 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Karter, D. H. Thom, J. Liu, H. H. Moffet, A. Ferrara, and J. V. Selby Use of Antibiotics Is Not Associated With Decreased Risk of Myocardial Infarction Among Patients With Diabetes Diabetes Care, July 1, 2003; 26(7): 2100 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Malik JournalScan Heart, June 1, 2003; 89(6): 695 - 695. [Full Text] [PDF]
|
|
|
|
|
|
P. Khairy, S. Rinfret, J.-C. Tardif, R. Marchand, S. Shapiro, J. Brophy, and J. Dupuis Absence of Association Between Infectious Agents and Endothelial Function in Healthy Young Men Circulation, April 22, 2003; 107(15): 1966 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zahn, S. Schneider, B. Frilling, K. Seidl, U. Tebbe, M. Weber, M. Gottwik, E. Altmann, F. Seidel, J. Rox, et al. Antibiotic Therapy After Acute Myocardial Infarction: A Prospective Randomized Study Circulation, March 11, 2003; 107(9): 1253 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Higgins Chlamydia pneumoniae and Coronary Artery Disease: The Antibiotic Trials Mayo Clin. Proc., March 1, 2003; 78(3): 321 - 332. [Abstract] [PDF]
|
|
|
|
 |
|
 S. V Pislaru, M. Van Ranst, C. Pislaru, Z. Szelid, G. Theilmeier, J.M Ossewaarde, P. Holvoet, S. Janssens, E. Verbeken, and F. J Van de Werf Chlamydia pneumoniae induces neointima formation in coronary arteries of normal pigs Cardiovasc Res, March 1, 2003; 57(3): 834 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Horne, J. B. Muhlestein, J. F. Carlquist, T. L. Bair, T. E. Madsen, N. I. Hart, J. L. Anderson, and for the Intermountain Heart Collaborative (IHC) St Statin Therapy Interacts With Cytomegalovirus Seropositivity and High C-Reactive Protein in Reducing Mortality Among Patients With Angiographically Significant Coronary Disease Circulation, January 21, 2003; 107(2): 258 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Kalayoglu, P. Libby, and G. I. Byrne Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease JAMA, December 4, 2002; 288(21): 2724 - 2731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Forrester Prevention of Plaque Rupture: A New Paradigm of Therapy Ann Intern Med, November 19, 2002; 137(10): 823 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sander, K. Winbeck, J. Klingelhofer, T. Etgen, and B. Conrad Reduced Progression of Early Carotid Atherosclerosis After Antibiotic Treatment and Chlamydia pneumoniae Seropositivity Circulation, November 5, 2002; 106(19): 2428 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Ezzahiri, H.J.M.G Nelissen-Vrancken, H.A.J.M Kurvers, F.R.M Stassen, I Vliegen, G.E.L.M Grauls, M.M.L van Pul, P.J.E.H.M Kitslaar, and C.A Bruggeman Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice Cardiovasc Res, November 1, 2002; 56(2): 269 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Delahaye, E. P. McFadden, and G. de Gevigney The scourge of coronary disease in diabetic patients: will antibiotics sweeten the pill? Eur. Heart J., October 2, 2002; 23(20): 1557 - 1559. [Full Text] [PDF]
|
|
|
|
|
|
J.A. Erkens, O.H. Klungel, R.M.C. Herings, R.P. Stolk, J.A. Spoelstra, D.E. Grobbee, and H.G.M. Leufkens Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients Eur. Heart J., October 2, 2002; 23(20): 1575 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F.M. Stone, M. A. Mendall, J.-C. Kaski, T. M. Edger, P. Risley, J. Poloniecki, A. J. Camm, and T. C. Northfield Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA) Circulation, September 3, 2002; 106(10): 1219 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Kerrigan, I. Douglas, A. Wray, J. Heath, M. F. Byrne, D. Fitzgerald, and D. Cox A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation Blood, June 28, 2002; 100(2): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wiesli, W. Czerwenka, A. Meniconi, F. E. Maly, U. Hoffmann, W. Vetter, and G. Schulthess Roxithromycin Treatment Prevents Progression of Peripheral Arterial Occlusive Disease in Chlamydia pneumoniae Seropositive Men: A Randomized, Double-Blind, Placebo-Controlled Trial Circulation, June 4, 2002; 105(22): 2646 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Tapia, A. Slepenkin, E. Sevrioukov, K. Hamor, L. M. de la Maza, and E. M. Peterson Inclusion Fluorescent-Antibody Test as a Screening Assay for Detection of Antibodies to Chlamydia pneumoniae Clin. Vaccine Immunol., May 1, 2002; 9(3): 562 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Parchure, E. G. Zouridakis, and J. C. Kaski Effect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and Evidence of Chlamydia pneumoniae Infection Circulation, March 19, 2002; 105(11): 1298 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Gorelick Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy: An Invited Review Stroke, March 1, 2002; 33(3): 862 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Levinson and R. J. Elin What Is C-Reactive Protein Telling Us About Coronary Artery Disease? Arch Intern Med, February 25, 2002; 162(4): 389 - 392. [Full Text] [PDF]
|
|
|
|
|
|
R. Tavendale, D. Parratt, S.D. Pringle, R. A'brook, and H. Tunstall-Pedoe Serological markers of Chlamydia pneumoniae infection in men and women and subsequent coronary events. The Scottish Heart Health Study Cohort Eur. Heart J., February 2, 2002; 23(4): 301 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kutlin, P. M. Roblin, and M. R. Hammerschlag Effect of Prolonged Treatment with Azithromycin, Clarithromycin, or Levofloxacin on Chlamydia pneumoniae in a Continuous-Infection Model Antimicrob. Agents Chemother., February 1, 2002; 46(2): 409 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T O'malley, C.A Ludlam, R.A Riemermsa, and K.A.A Fox Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1). Potential risk factor for the acute coronary syndromes Eur. Heart J., July 2, 2001; 22(14): 1226 - 1234. [Abstract] [PDF]
|
|
|
|
 |
|
 C. H. Selzman, S. A. Miller, and A. H. Harken Therapeutic implications of inflammation in atherosclerotic cardiovascular disease Ann. Thorac. Surg., June 1, 2001; 71(6): 2066 - 2074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. LaBiche, D. Koziol, T. C. Quinn, C. Gaydos, S. Azhar, G. Ketron, S. Sood, and T. J. DeGraba Presence of Chlamydia pneumoniae in Human Symptomatic and Asymptomatic Carotid Atherosclerotic Plaque Stroke, April 1, 2001; 32(4): 855 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sander, K. Winbeck, J. Klingelhofer, T. Etgen, and B. Conrad Enhanced Progression of Early Carotid Atherosclerosis Is Related to Chlamydia pneumoniae (Taiwan Acute Respiratory) Seropositivity Circulation, March 13, 2001; 103(10): 1390 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. de Boer, A. C. van der Wal, M. A. Houtkamp, J. M. Ossewaarde, P. Teeling, and A. E. Becker Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae Cardiovasc Res, December 1, 2000; 48(3): 402 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Muhlestein, J. L. Anderson, J. F. Carlquist, K. Salunkhe, B. D. Horne, R. R. Pearson, T. J. Bunch, A. Allen, S. Trehan, and C. Nielson Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease : Primary Clinical Results of the ACADEMIC Study Circulation, October 10, 2000; 102(15): 1755 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Slavkin and B. J. Baum Relationship of Dental and Oral Pathology to Systemic Illness JAMA, September 13, 2000; 284(10): 1215 - 1217. [Full Text] [PDF]
|
|
|
|
|
|
G. Caligiuri, G. Paulsson, A. Nicoletti, A. Maseri, and G. K. Hansson Evidence for Antigen-Driven T-Cell Response in Unstable Angina Circulation, September 5, 2000; 102(10): 1114 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S A Morre, W Stooker, W K Lagrand, A J C van den Brule, and H W M Niessen Microorganisms in the aetiology of atherosclerosis J. Clin. Pathol., September 1, 2000; 53(9): 647 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability Cardiovasc Res, September 1, 2000; 47(4): 648 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mayr, S. Kiechl, J. Willeit, G. Wick, and Q. Xu Infections, Immunity, and Atherosclerosis : Associations of Antibodies to Chlamydia pneumoniae, Helicobacter pylori, and Cytomegalovirus With Immune Reactions to Heat-Shock Protein 60 and Carotid or Femoral Atherosclerosis Circulation, August 22, 2000; 102(8): 833 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Danesh, P. Whincup, M. Walker, L. Lennon, A. Thomson, P. Appleby, Y.-k. Wong, M. Bernardes-Silva, M. Ward, and R. West Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis Commentary: Adjustment for potential confounders may have been taken too far BMJ, July 22, 2000; 321(7255): 208 - 213. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. W. Fong Emerging relations between infectious diseases and coronary artery disease and atherosclerosis Can. Med. Assoc. J., July 1, 2000; 163(1): 49 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.J. Camm and K.M. Fox Chlamydia pneumonia (and other infective agents) in atherosclerosis and acute coronary syndromes. How good is the evidence? Eur. Heart J., July 1, 2000; 21(13): 1046 - 1051. [PDF]
|
|
|
|
|
|
M. S. V. Elkind, I-F. Lin, J. T. Grayston, and R. L. Sacco Chlamydia pneumoniae and the Risk of First Ischemic Stroke : The Northern Manhattan Stroke Study Stroke, July 1, 2000; 31(7): 1521 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ericson, T. G. P. Saldeen, O. Lindquist, C. Pahlson, and J. L. Mehta Relationship of Chlamydia pneumoniae Infection to Severity of Human Coronary Atherosclerosis Circulation, June 6, 2000; 101(22): 2568 - 2571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. X. Bin, K. Wolf, T. Schaffner, and R. Malinverni Effect of Azithromycin plus Rifampin versus Amoxicillin Alone on Eradication and Inflammation in the Chronic Course of Chlamydia pneumoniae Pneumonitis in Mice Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1761 - 1764. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. D. Wright, C. Burton, M. Hernandez, H. Hassing, J. Montenegro, S. Mundt, S. Patel, D. J. Card, A. Hermanowski-Vosatka, J. D. Bergstrom, et al. Infectious Agents Are Not Necessary for Murine Atherogenesis J. Exp. Med., April 17, 2000; 191(8): 1437 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gurfinkel, G. Bozovich, B. Mautner, J. L. Anderson, J. B. Muhlestein, J. Carlquist, A. Allen, S. Trehan, C. Nielson, S. Hall, et al. Chlamydia pneumoniae in Coronary Artery Disease • Response Circulation, March 28, 2000; 101 (12): e118 - e119. [Full Text] [PDF]
|
|
|
|
|
|
E. Gurfinkel, G. Bozovich, and B. Mautner Chlamydia pneumoniae in Coronary Artery Disease Circulation, March 14, 2000; 101 (10): e95 - e95. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Quaschning and C. Wanner The role of Chlamydia in coronary heart disease--fact or fiction? Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2800 - 2803. [Full Text] [PDF]
|
|
|
|
|
|
A. Shor and J. I. Phillips Chlamydia pneumoniae and Atherosclerosis JAMA, December 1, 1999; 282(21): 2071 - 2073. [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Grayston Does Chlamydia pneumoniae Cause Atherosclerosis? Arch Surg, September 1, 1999; 134(9): 930 - 934. [Full Text] [PDF]
|
|
|
|
 |
|
 Jury Out on Antibiotic Therapy for CAD Prevention Journal Watch Dermatology, June 1, 1999; 1999(601): 17 - 17. [Full Text]
|
|
|
|
 |
|
 Antibiotics for Coronary Artery Disease Journal Watch Infectious Diseases, May 1, 1999; 1999(501): 7 - 7. [Full Text]
|
|
|
|
 |
|
 Jury Out on Antibiotic Therapy for Coronary Prevention Journal Watch (General), April 9, 1999; 1999(409): 1 - 1. [Full Text]
|
|
|
|
|
|
J. T. Grayston Antibiotic Treatment Trials for Secondary Prevention of Coronary Artery Disease Events Circulation, March 30, 1999; 99(12): 1538 - 1539. [Full Text] [PDF]
|
|
|
|
|
|
J. Sinisalo, K. Mattila, V. Valtonen, O. Anttonen, J. Juvonen, J. Melin, H. Vuorinen-Markkola, M. S. Nieminen, and for the Clarithromycin in Acute Coronary Syndrome Effect of 3 Months of Antimicrobial Treatment With Clarithromycin in Acute Non-Q-Wave Coronary Syndrome Circulation, April 2, 2002; 105(13): 1555 - 1560. [Abstract] [Full Text] [PDF]
|
|